Moss, 22 July 2024

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, is pleased to announce that Matti Heinonen* is appointed to the position
of CEO. Matti brings extensive experience from leading positions in the global
healthcare industry, with focus on the diagnostics and pharma segments.

Throughout his career, Matti has delivered exceptional achievements for global
companies, like Amgen, with focus on driving profitable growth. During the last
3 years, Matti has acted as VP Immunodiagnostics and most recently as CCO for
Medix Biochemica. Medix is a well-established raw material supplier for the
international diagnostics industry. Matti is a citizen of Finland, and he has
previous international experience from the US and Europe. Matti will take on the
role no later than February 2025.

"Gentian's mission to protect lives and reduce costs by enabling better
treatment decisions with significantly greater operational efficiency is truly
inspiring. The company boasts a strong team with a proven track record, having
achieved impressive results. Gentian's ambition to become a leading diagnostic
partner, serving millions of patients, is both exciting and credible." says
Matti Heinonen, incoming CEO of Gentian Diagnostics.

"We are looking forward to working with Matti and together steering Gentian
Diagnostics to the next level of growth. We are convinced that Matti's
background as Master of Biochemistry combined with business acumen coming from
international leadership positions in our industry will secure our ambition of
continuous double-digit profitable sales growth.," says Hilja Ibert, chairperson
of the board.

* Please note that Matti has recently reassumed his birth name Heinonen. Before
he has worked for several years under the last name Arvela. 

For further information please contact: 
Hilja Ibert, Chairperson of the Board 
hilja.ibert@gentian.no 
+47 919 05 242 (mobile)

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Gentian's expertise and focus lies within homogenous
immunoassays, specifically infections, inflammations, kidney failures and
congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is
headquartered in Moss, Norway, serving the global human and veterinary
diagnostics markets through sales and representative offices in Sweden, USA, and
China. For more information, please visit www.gentian.com.


This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act.